Zusammenfassung
Mit der Einführung der Megavolttherapie wurde die Indikation einer Bestrahlung von Harnblasenkarzinomen teilweise unabhängig von der Größe der Tumorinvasion gestellt. Die nicht immer günstigen Ergebnisse, aber auch die inzwischen durch das TNM-System und das Grading sehr differenzierte Einteilung der urothelialen Tumoren hat dazu geführt, daß praktisch nur noch bei etwa einem Viertel der Patienten die Indikation einer Bestrahlung diskutiert wird. Tabelle 1 zeigt die Häufigkeit der verschiedenen Blasentumoren in Abhängigkeit von der T-Kategorie und vom Malignitätsgrad. So wird bei den häufigsten Tumoren der Klassifikation Ta Gl die Behandlung mit der transurethralen Resektion abgeschlossen sein. Die Tabelle zeigt weiter, daß fortgeschrittene Tumoren und auch Tumoren mit einem ungünstigen Grading seltener vorkommen. Hier ist die Indikation der Bestrahlung gegeben. Während bisher die Indikation der Bestrahlung als prä- oder postoperative bzw. alleinige Maßnahme diskutiert wurde, ist in den letzten Jahren mit Erfolg versucht worden, durch zytostatische Substanzen, wie Cisplatin, Adriamycin oder 5-Fluorouracil die Wirkung der Bestrahlung zu verstärken. Aufgrund der bisher vorliegenden Daten können möglicherweise durch die zuletzt genannten kombinierten Verfahren bessere Ergebnisse erzielt werden, so daß die Indikation einer Bestrahlung an Bedeutung gewinnen wird. Ein entscheidender Gesichtspunkt ist in diesem Zusammenhang, daß durch solche Behandlungskonzepte bei einem Teil der Patienten die Harnblase mit ausreichender Funktion erhalten bleibt.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Ammon J, Frik W, Karstens JH, Rübben H, Schoffers J (1979) Ganzkörper-Computertomographie bei Erkrankungen des urogenitalen Systems. Urologe [A] 18:1–7
Ammon J, Karstens JH, Rathert P (1981) Urologische Onkologie, Radiologische Diagnostik und Strahlentherapie, 2. Auflage. Springer, Berlin Heidelberg New York
Ang KK, van der Schueren E (1982) The tolerance to multiple daily fractionated radiotherapy for the treatment of prostatic and bladder carcinoma: a feasibility study. Int J Radiat Biol 8:1665–1670
Batata MA, Chu FCH, Hilaris BS, et al. (1981) Factors of prognostic and therapeutic significance in patients with bladder cancer. Int J Radiat Oncol Biol Phys 7:575
Belli JA, Piro AJ (1977) The interaction between radiation and adriamycin damage in mammalian cells. Cancer Res 37:1624–1628
Blandy JP, England HR, Evans SJW, Hope-Stone HF, Mair GMM, Mantell BS, Oliver RTD, Paris AMI, Risdon RA (1980) T3 Bladder cancer — the case for salvage cystectomy. Br J Urol 52:506–510
Bloom HJG, Hendry WF, Wallace DM, Skeet RG (1982) Treatment of T3 bladder cancer: controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Br J Urol 54:136–151
Bukowski RM, Montie JE, Pontes EJ (1987) Neoadjuvant chemotherapy of locally advanced transitional cell carcinoma of the bladder — results of a phase II trial and follow-up. (Abstr.) Proc Am Soc Clin Oncol 6:108
Byfield JE et al. (1982) Pharmacologic requirements for obtaining sensitization of human tumor cell in vitro to combined 5-fluorouracil or ftorafur and x-rays. Int J Radiat Oncol Biol Phys 8:1923–1933
Caspers RJL, Hop WCJ (1983) Irradiation of true pelvis for bladder and prostatic carcinoma in supine, prone or Trendelenburg position. Int J Radiat Oncol Biol Phys 9:589–593
Dembo AJ (1987) Time-dose factors in chemotherapy: Expanding the concept of doseintensity. J Clin Oncol 5:694–696
Dewit L (1987) Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 13:403–426
Duncan W, Quilty PM (1986) The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage x-ray therapy. Radiother Oncol 7:299–310
Duncan W, Williams JR, Kerr GR, Arnott SJ, Quilty PM, Rodger A, MacDougall RH, Jack WJL (1986) An analysis of the radiation related morbidity observed in a randomized trial of neutron therapy for bladder cancer. Int J Radiat Oncol Biol Phys 12:2085–2092
Elkind MM, Sutton-Gilbert H, Moses WB, Kamper C (1967) Sublethal and lethal radiation damage. Nature 214:1088–1092
Ernst H, Besserer A (1987) Tumoren der Harnblase. In: E. Scherer (Hrsg.) Strahlentherapie, Radiologische Onkologie, 3. Auflage. Springer, Berlin Heidelberg New York London Paris Tokyo
Enig B, Winther E, Hessov I (1986) Nutritional status of patients with cancer of the bladder before and during radiation therapy. Influence on survival? Radiother Oncol 5:277–285
Fossa SD (1985) Irradiation of advanced bladder cancer (T4). In: Pavone-Macaluso M, Smith PH, Bagshaw MA, Testicular cancer and other tumors of the genitourinary tract. Plenum Press, New York London
Fossa SD et al. (1987) Pre-cystectomy chemotherapy in patients with muscle infiltrating bladder carcinoma. Scand J Urol Nephrol 21:39–42
Füller J, Fritzsche V, Kob D, Arndt J, Kriester A (1986) Histologische Veränderungen der normalen Harnblasenwand nach verschieden fraktionierter Bestrahlung — eine tierexperimentelle Studie. Strahlenther Onkol 162:519–524
Fritsch E, Jakse G, Frommhold H (1985) Kombinierte Radio-/Chemotherapie des invasiven Harnblasenkarzinoms. Fortschr Roentgenstr 142:654–658
Gowin W (1983) Die Bedeutung des Wirbelsäulenvenensystems bei der Metastasenbildung. Strahlenther Onkol 159:682–689
Gunderson RL (1987) Adjuvant irradiation of rectal cancer. Int J Radiat Oncol Biol Phys 13:141–142
Herr HW (1985) Preoperative irradiation with and without chemotherapy as adjunct to radical cystectomy. Urology 25:127–134
Hryniuk WM (1987) Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 14:65–74
Jakse G, Frommhold H, Zur Nedden D (1985) Combined radiation and chemotherapy for locally advanced transitional cell carcinoma of the urinary bladder. Cancer 55:1659–1664
Jakse G, Rauschmeier H, Fritsch E, Frommhold H, Marberger H (1986) Die integrierte Radiotherapie und Chemotherapie des lokal fortgeschrittenen Harnblasenkarzinoms. Aktuel Urol 17:68–73
Jakse G, Fritsch E, Frommhold H (1987) Hyperfractionated, accelerated radiotherapy and concurrent chemotherapy in locally advanced bladder cancer. Eur Urol 13:22–25
Jakse G, Fritsch E, Frommhold H (1987) Combined cisplatinum and radiation therapy in locally advanced bladder cancer: an up-date. (Abstr.) J Urol 137:268 A
Klein FA, Whitmore WF, Wolf RM, Herr HW, Sogani PC, Staiano-Coico L, Melamed MR (1983) Presumptive downstaging from preoperative irradiation for bladder cancer as determined by flow cytometry: preliminary report. Int J Radiat Oncol Biol Phys 9:487–491
Kob D, Arndt J, Kriester A, Schwenk M, Kloetzer KH (1985) Ergebnisse der perkutanen Strahlentherapie bei Harnblasenkarzinomen mit Einserien- und Zweiserienbestrahlung. Strahlenther Onkol 161:673–677
Kyriazis AP, Yagoda A, Kereiakes JG, Kyriazis AA, Whitmore WF (1983) Experimental studies on the radiation-modifying effect of cis-diamminedichloroplatinum II ( DDP) in human bladder transitional cell carcinoma grown in nude mice. Cancer 52:452–457
Lindeil O (1987) Salvage Cystectomy. Eur Urol 13:17–21
Macchia RJ (1988) Editorial comment. Urology Suppl 21:3–4
Mahadevia PS, Koss LG, Tar IJ (1986) Prostatic Involvement in bladder cancer. Prostate Mapping in 20 cystoprostatectomy specimens. Cancer 58:2096–2102
Marks LB, Prout GR, Kaufman SD, Griffin PP etal. (1987) Invasive bladder cancer: MCV (methotrexate, cisplatin, vinblastine) followed by cisplatin plus pelvic irradiation and possible cystectomy: patient tolerance and local tumor response (Abstr.) Proc Am Soc Clin Oncol 7:101
Miller AB et al. (1981) Reporting results of cancer treatment. Cancer 47:207–214
Mohiuddin M, Kramer S, Newall J, Parsons J, Wiley A, Strong G, Mulholland SG (1985) Combined preoperative and postoperative radiation for bladder cancer. Cancer 55:963–966
Peters LJ, Ang KK (1986) Unconventional fractionation schemes in radiotherapy. In: De Vita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology. J. B. Lippincott Company, Philadelphia London Mexiko City New York St. Louis Sao Paulo Sydney
Quilty PM, Kerr GR, Duncan W (1987) Prognostic indices for bladder cancer: An analysis of patients with transitional cell carcinoma of the bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol 7:311–321
Quilty PM, Duncan W (1986) Primary radical radiotherapy for T3 transitional cell cancer of the bladder: an analysis of survival and control. Int J Radiat Oncol Biol Phys 12:853–860
Quilty PM, Duncan W (1986) Radiotherapy for squamous carcinoma of the urinary bladder. Int J Radiat Oncol Biol 12:861–865
Richie JP, Shipley WU, Yagoda A (1985) Cancer of the bladder. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer Principles & Practice of Oncology, 2nd Edition, J. B. Lippincott Company, Philadelphia London Mexico City New York St. Louis Sao Paulo Sydney
Rotman M, Aziz H (1987) Bladder carcinoma. In: Perez CA, Brady LW (eds) Principles and Practice of Radiation Oncology, J. B. Lippincott Company, Philadelphia London Mexico City New York St. Louis Sao Paulo Sydney
Rotman M, Macchia R, Silverstein M, Aziz H, Choi K, Rosenthal J, Braverman A, Laungani GB (1987) Treatment of advanced bladder carcinoma with irradiation and concomitant 5-fluorouracil infusion. Cancer 59:710–714
Russell AH, Markette K, Tong DY (1984) Intracavitary irradiation for carcinoma of the urinary bladder: rationale, technique, and preliminary results. Int J Radiat Oncol Biol Phys 10:215–219
Russell KJ, Boileau MA, Ireton RC et al. (1988) Transitional cell carcinoma of the urinary bladder: histologic clearance with combined 5-FU chemotherapy and radiation therapy. Radiology 167:845–848
Rübben H (1985) Nachsorgerichtlinien beim Harnblasenkarzinom. Urologe [B] 25:275–280
Rübben H, Lutzeyer W, Mittermayer Ch, Ammon J (1986) Urotheliale Harnblasentumoren. Dtsch Ärztebl 63:552–556
Sauer R, Sehrott KM, Dunst J, Thiel HJ, Sigel A (1987) Improved response rate of T3/T4-carcinomas of the urinary bladder treated by radiotherapy under cisplatin sensibilisation (Abstr.) Int J Radiat Oncol Biol Phys 13, Suppl 1:101
Scanlon PW, Scott M, Segura JW (1983) A comparison of short-course, low-dose and long-course, high-dose preoperative radiation for carcinoma of the bladder. Cancer 52:1153–1159
Scher H, Reuter V, Sternberg C, Herr H, Whitmore W, Morse M, Sogani P, Fair W, Yagoda A (1987) Pathologic response to M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) in urothelial tract tumors. (Abstr.) Proc Am Soc Clin Oncol 6:105
Scherer E (1980) Tumoren der Harnblase. In: E. Scherer (Hrsg) Strahlentherapie, Radiologische Onkologie, 2. Auflage. Springer, Berlin Heidelberg New York London Paris Tokyo
Shipley WU, Coombs LJ, Einstein AB, Soloway MS, Wajsman Z, Prout GR (1984) National bladder cancer collaborative group. Cisplatin and full dose irradiation for patients with invasive bladder carcinoma: a preliminary report of tolerance and local response. J Urol 132:899–903
Shipley WU, Rose MA, Perrone TL, Mannix CM, Heney NM, Prout GR (1985) Full-dose irradiation for patients with ivasive bladder carcinoma: clinical and histological prognostic factors of improved survival. J Urol 134:679–683
Shipley WU, Rose MA (1985) Bladder cancer. The selection of patients for treatment by full-dose irradiation. Cancer 55:2278–2284
Shipley WU, Einstein AB, Prout GR, Brannen GE, Flanagan MJ, Koontz WE, Pearse H, Barton BA, Englander L, Weinstein R (1987) Cisplatin and full-dose irradiation for patients with invasive bladder carcinoma: the national bladder cancer group experience. (Abstr.) J Urol 137:155 A
Smith JA, Batata M, Grabstald H, Sogani PC, Herr H, Whitmore WF, jr (1982) Preoperative irradiation and cystectomy for bladder cancer. Cancer 49:869–873
Sternberg, CN, Yagoda, A, Scher HI etal. (1988) M-VACV (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139:461–469
Sternberg CN, Yagoda A, Scher HI, Herr HW, Morse MJ, Sogani PC, Watson RC, Hollander PS, Whitmore WF (1987) Long-term survival in advanced urothelial cancer with M-VAC: the first two years of accrual. (Abstr.) J Urol 137:157 A
Studer UE, von Essen CF, Enderli JB, Bodendörfer G, Zingg EJ (1985) Preliminary results of a phase I/II study with pi-meson (pion) treatment for bladder cancer. Cancer 56:1943–1952
Tepper JE, Wood WC, Cohen AM, Shipley WU, Orlow E, Hedberg SE, Warshaw AL, Nardi GL, Biggs PJ (1985) Intraoperative radiation therapy 12. In: DeVita VT, Hellman S, Rosenberg SA (eds) Important Advances in Oncology. J. B. Lippincott Company, Philadelphia London Mexico City New York St. Louis Sao Paulo Sydney
Timmer PR, Hartlief HA, Hooijkaas JAP (1985) Bladder cancer: pattern of recurrence in 142 patients. Int J Radiat Oncol Biol Phys 11:899–905
Toohill RJ et al. (1987) The effects of delay in standard treatment due to induction chemotherapy in two randomized prospective studies. Laryngoscope 97:407–412
Troner M, Birch R, Omura GA, Williams S (1987) Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a southeastern cancer study group trial. J Urol 137:660–662
UICC (1987) TNM Classification of malignant tumours. Eds: Hermanek P, Sobin LH, 4th Edition. Springer, Berlin Heidelberg New York London Paris Tokyo
van der Werf-Messing B, Friedeil GH, Raigopal SM, et al. (1982) Carcinoma of the urinal bladder T3NxM0 treated by preoperative irradiation followed by cystectomy. Int J Radiat Oncol Biol Phys 8:1849
van der Werf-Messing B, Menon RS, Hop WCJ (1983) Carcinoma of the urinary bladder category T3NxM0 treated by the combination of radium implant and external irradiation: second report. Int J Radiat Oncol Biol Phys 9:177–180
van der Werf-Messing B, Menon RS, Hop WCJ (1983) Cancer of the urinary bladder category T2, T3 (NxM0) treated by interstitial radium implant: second report. Int J Radiat Oncol Biol Phys 9:481–485
Yu WS, Sagerman RH, Chung ChT, Dalai PS, King GA (1985) Bladder carcinoma. Experience with radical and preoperative radiotherapy in 421 patients. Cancer 56: 1293–1299
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Ammon, J., Gehl, HB., Karstens, J.H. (1988). Strahlentherapie des Harnblasenkarzinoms. In: Bichler, KH., Flüchter, S.H., Strohmaier, W.L. (eds) Therapie des Harnblasenkarzinoms. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72670-5_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-72670-5_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-72671-2
Online ISBN: 978-3-642-72670-5
eBook Packages: Springer Book Archive